Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of “Moderate Buy” by Analysts

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has received an average recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 1 year price target […]